Circ_0003855 involvement of esophageal cancer progression through miR-622/FLOT1

To confirm the relationship between Circ_0003855 and EC,we purchased the Human esophageal carcinoma cell line Eca109 and normal human esophageal epithelial cells HEEC,and the expression levels of Circ_0003855,miR-622,and FLOT1 were detected.The results show that Circ_0003855 and FLOT1 were highly expressed in Eca109 cells,while miR-622 was lowly expressed(p<0.05).Subsequently,Circ_0003855 small interfering RNA(si-Circ_0003855)and its negative control(si-NC)were used to detect changes in cellular biological behaviors.We found that the activity of Eca109 cells was reduced after interfering with the expression of Circ_0003855,and miR-622 expression was elevated,while FLOT1 was decreased(p<0.05).Additionally,si-Circ_0003855 and miR-622 inhibitor sequence(miR-622-inhibition)were co-transfected into cells with miR-622-inhibition alone,and untreated Eca109 cells were used as a control to detect the expression of FLOT1.Co-transfection of si-Circ_0003855 and miR-622-inhibition showed no significant difference in FLOT1 expression compared to the control cells(p>0.05).Synthesizing the results of these experiments above,we believe that interfering with the expression of Circ_0003855 can inhibit the activity of EC cells,and its mechanism is related to miR-622 and FLOT1.

Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma

BACKGROUND The clinical effects and detailed roles of long non-coding RNA(LncRNA)steroid receptor RNA activator 1(SRA1)in esophageal squamous cell carcinoma(ESCC)remain ambiguous.In the present study,the complementary sites between lncRNA SRA1,miRNA-363-5p,and phospholysine phosphohistidine inorganic pyrophosphate phosphatase(LHPP)predicted via bioinformatics analysis stimulated us to hypothesize that miRNA-363-5p/LHPP axis might be required for SRA1-mediated ESCC progression.AIM To investigate the molecular events of SRA1 in the malignant behavior in ESCC.METHODS Thirty-eight ESCC tissues and paired adjacent normal tissues were acquired.SRA1 expression was detected in ESCC tissues and cell lines using quantitative reverse transcription-polymerase chain reaction.Cell counting Kit-8 assay,transwell invasion assay,glycolysis assay,and xenograft tumor model were performed to address the malignant biological behaviors of ESCC cells after the introduction of SRA1.The t-test and theχ2 test were used for comparison between groups.Survival curve analysis was performed using the Kaplan-Meier method.RESULTS SRA1 downregulation was identified in ESCC.ESCC patients exhibiting a low SRA1 expression faced shorter overall survival than those with a high SRA1 expression.The introduction of SRA1 inhibited cell proliferation,glucose uptake,and lactate production in ESCC.In vivo,the growth of ESCC was hindered by SRA1 overexpression.Then,SRA1 overexpresses the LHPP by inhibiting miRNA-363-5p.Lastly,the introduction of small interfering RNA si-LHPP or miRNA-363-5p mimic could abrogate the inhibition roles triggered by SRA1.CONCLUSION SRA1 inhibits the oncogenicity of ESCC via miRNA-363-5p/LHPP axis.The SRA1/miRNA-363-5p/LHPP pathway may be a therapeutic target for ESCC.

Value of long non-coding RNA Rpph1 in esophageal cancer and its effect on cancer cell sensitivity to radiotherapy

BACKGROUND Esophageal cancer is a common digestive tract tumor that is generally treated with radiotherapy.Poor responses to radiotherapy in most patients generally result in local radiotherapy failure,so it is essential to find new radiosensitizers that can enhance the response of cancer cells to radiotherapy and improve the survival of esophageal cancer patients with radiation resistance.The long noncoding RNA(lncRNA)Rpph1 is highly expressed in human gastric cancer tissues,and represses breast cancer cell proliferation and tumorigenesis.However,the expression of lncRNA Rpph1 in esophageal cancer and its relationship with radio-sensitivity has not been studied.AIM To explore the value of lncRNA Rpph1 in esophageal cancer and its effect on cancer cell sensitivity to radiotherapy.METHODS Eighty-three patients with esophageal cancer admitted to Qilu Hospital of Shandong University and 90 healthy participants who received physical examinations were collected as research participants.The expression of Rpph1 was determined by qRT-PCR.siRNA-NC and siRNA-Rpph1 were transfected into esophageal cancer cell lines,and cells without transfection were designated as the blank control group.Cell survival was tested by colony formation assays,and the levels of proteins related to apoptosis and epithelial-mesenchymal transitions were determined by Western blot assays.Cell proliferation was assessed by MTT assays,cell apoptosis by flow cytometry,and cell migration by wound-healing assays.Changes in cell cycle distribution were monitored.RESULTS Rpph1 was highly expressed in esophageal carcinoma,making it a promising marker for the diagnosis of esophageal cancer.Rpph1 could also be used to distinguish different short-term responses,T stages,N stages,and clinical stages of esophageal cancer patients.The results of 3-year overall survival favored patients with lower Rpph1 expression over patients with higher Rpph1 expression(P<0.05).In vitro and in vivo experiments showed that silencing Rpph1 expression led to higher sensitivity of esophageal cancer cells to radiotherapy,stronger apoptosis in esophageal cancer cells induced by radiotherapy,higher expression of Bax and caspase-3,and lower expression of Bcl-2(Bax,caspase-3,and Bcl-2 are apoptosis-related proteins).Additionally,silencing Rpph1 attenuated radiation-induced G2/M phase arrest,and significantly inhibited the expression of proteins involved in cell proliferation,migration,and epithelial-mesenchymal transition regulation in esophageal cancer cells.CONCLUSION Rpph1 is highly expressed in esophageal cancer.Silencing Rpph1 expression can promote cell apoptosis,inhibit cell proliferation and migration,and increase radio-sensitivity.

Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China

AIM: To analyze the relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 andKazakh's esophageal squamous cell cancer in China.METHODS: The genotypes of cytochromes P450 (CYP) 2E1 and glutathione S-transferase (GST) M1 were investigated by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) following PCR in 104 Kazakh's patients with esophageal cancer (EC) and 104 non-cancer controls.RESULTS: The frequency of CYP2E1 c1/c1 genotype was significantly higher in patients with cancer (77.9%) thanin control subjects (24.0%) (P＜0.05; OR, 11.13; 95%CI,5.84-21.22). The difference of GSTM1 null was significantly more frequent in the cancer (34.6%) vsthe control group (3.8%) (P＜0.05; OR, 13.24; 95%CI, 4.50-38.89). On the other hand, the combination of GSTM1 presence and CYP2E1 c1/c1 genotypes increased the risk for cancer (P＜0.05;OR, 13.42; 95%CI, 6.29-28.3).CONCLUSION: The CYP2E1 c1/c1, GSTM1 deletion genotypes are genetically susceptible biomarkers for ESCC in Kazakh population. Individuals with allele c1 of RsaI polymorphic locus for CYP2E1 may increase the risk of ESCC. Moreover, CYP2E1 wild type (c1/c1) increased thesusceptibility to ESCC risk in Kazakh individuals with GSTM1 presence genotype.

Immunotherapy for esophageal cancer:Where are we now and where can we go

Immune checkpoint inhibitor therapy has dramatically improved patient prognosis,and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma(ESCC)in the past decade.Monoclonal antibodies that selectively inhibit programmed cell death-1(PD-1)activity has now become standard of care in the treatment of ESCC in metastatic settings,and has a high expectation to provide clinical benefit during perioperative period.Further,anti-cytotoxic T-lymphocyte–associated protein 4(CTLA-4)monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody.Well understanding of the existing evidence of immune-based treatments for ESCC,as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant,adjuvant,and metastatic diseases,may provide future prospects of ESCC treatment for better patient outcomes.

Role of the Na^+/K^+/2Cl^- cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma

AIM: To investigate the role of Na+/K+/2Cl- cotransporter 1 (NKCC1) in the regulation of genes involved in cell cycle progression and the clinicopathological significance of its expression in esophageal squamous cell carcinoma (ESCC).

Association between esophageal cancer risk and EPHX1 polymorphisms:A meta-analysis

AIM: To summarize the relationship between p.Tyr113His and p.His139Arg polymorphisms in microsomal epoxide hydrolase (EPHX1) and risk for esophageal cancer (EC).

COMBINED DETECTION OF CYCLIN D1,P27 AND DNA CONTENT IN ESOPHAGEAL CANCER

Objective： To investigate the expressions of cyclin D1 and p27 and DNA content in esophageal cancer and adjacent normal tissues, and to discuss the relationship between them. Methods： The cyclinD1 and p27 were detected by immunohistochernical staining; DNA content was measured by flow cytometry. Results： The positive expression rates of cyclinD1 and p27 in cancer were 45.8% and 33.3% respectively, the DNA content in the positive group of cyclinD1 was higher than that in the negative group of cyclinDl（1.54±0.21 versus 1.08i-0.43, P〈0.05）, while the DNA content and SPF （S-phase fraction） in the positive group of p27 were lower than those in the negative group （1.10±0.19 and 5.56%±5.18% versus 1.66±0.28 and 19.78%±6.12%, P〈0.05）. Conclusion： The data show that the expression of cyclinD1 and p27 are related to the ontogenesis and progression of esophageal cancer. The combined detection of cyclinD1, p27 and DNA content may be indicators of diagnosis and assessment of esophageal cancer.

Relationships of early esophageal cancer with human papillomavirus and alcohol metabolism

BACKGROUND It is well known that an alcohol consumption habit together with inactive heterozygous aldehyde dehydrogenase-2(ALDH2)is an important risk factor for the development of esophageal squamous cell carcinoma(ESCC).It remains controversial whether human papillomavirus(HPV)infection contributes to the occurrence/development of ESCC.There has been no study in which the relationship between ESCC and HPV in addition to alcohol dehydrogenase-1B(ADH1B)and ALDH2 genotypes was evaluated.AIM To evaluate relationships between HPV infection and development of esophageal cancer,particularly early esophageal cancer,based on ADH1B/ALDH2 polymorphisms.METHODS We conducted an exploratory retrospective study using new specimens,and we enrolled 145 patients who underwent endoscopic resection for superficial ESCC and had been observed for more than two years by both physical examination and endoscopic examination in Hokkaido University Hospital.Saliva was collected to analyze genetic polymorphisms of ADH1B/ALDH2.We performed in situ hybridization for resected specimens to detect HPV by using an HPV type 16/18 probe.RESULTS HPV was detected in 15(10.3%)of the 145 patients with ESCC.HPV-positive rates in inactive ALDH2*1/*2 and ALDH2*1/*1+*2/*2 were 10.8%and 9.8%,respectively(P=1.00).HPV-positive rates in slow-metabolizing ADH1B*1/*1 and ADH1B*1/*2+*2/*2 were 12.0%and 10.0%,respectively(P=0.72).HPV-positive rates in the heavy or moderate alcohol consumption group and the light or rare consumption group were 11.1%and 8.7%,respectively(P=0.68).HPV-positive rates in the heavy smoking group and the light or no smoking group were 11.8%and 8.3%,respectively(P=0.59).The 3-year incidence rates of secondary ESCC or head and neck cancer after initial treatment in the HPV-positive and HPVnegative groups were 14.4%and 21.4%(P=0.22),respectively.CONCLUSION In the present situation,HPV status is considered to be less important than other risk factors,such as alcohol consumption,smoking habit,ADH1B/ALDH2 polymorphisms,and HPV status would therefore have no effect on ESCC risk management.

温郁金提取物对食管癌TE-1细胞增殖的抑制作用

目的研究温郁金提取物对食管癌TE-1细胞增殖的抑制作用。方法采用超临界CO2萃取法提取温郁金成分。将TE-1细胞贴壁后分成4组:1组加入100μL含0.1%DMSO的RMPI-1640培养基,作为对照组;另外3组分别加入浓度为25、50、100mg/L温郁金提取物完全培养液各100μL,分别作为温郁金低、中、高剂量组。培养48h后采用四甲基偶氮唑盐(MTT)比色法测定各组TE-1细胞生长抑制率。应用基因芯片技术检测各组TE-1细胞基因表达谱的变化。对差异表达基因进行基因本体(gene ontology,GO)功能分类。结果与对照组比较,温郁金各剂量组生长抑制率均升高,差异有统计学意义(P<0.05)。温郁金各剂量组TE-1细胞生长抑制率随着剂量升高而增加,差异均有统计学意义(P<0.05)。通过基因芯片筛选出温郁金提取物作用前后88个基因表达水平发生改变且有统计学意义,包括22个基因表达下调,66个基因表达上调。基因GO分类提示差异表达基因主要涉及信号传导(6个)、细胞周期(8个)、凋亡(14个)或分化调节(10个)等。结论温郁金提取物对人食管癌TE-1细胞生长有抑制作用,其抗肿瘤作用可能与调控多层次的基因表达改变有关。

食管癌TE-1细胞生物学性状的相关性研究

目的研究食管癌TE-1细胞生物学性状。方法①将购自上海生命科学院的食管癌TE-1细胞株进行HE染色;②用MTT法绘制细胞生长曲线;③免疫组织化学检测细胞特异性免疫标志;④流式细胞仪分析细胞周期。结果①用DMEM高糖培养基培养,生长良好。HE染色下,细胞大致分为3种:一种细胞呈椭圆形,核大,胞浆少,一种细胞呈三角形或多角形,大小,形态不等,一种细胞有双核或者多核,核大深染,染色质丰富,核分裂相多见;②细胞接种培养后其生长曲线呈近似S形。免疫组织化学检测3种抗体均表达阳性,其中CK7阳性表达定位于胞浆,Ki-67和p53定位于胞核;③TE-1细胞周期:半数细胞处于增生期,半数处于静止期。结论食管癌TE-1细胞符合食管鳞癌的特征。

siRNA干扰MACC1基因对食管癌细胞TE-1的生物学影响

目的通过siRNA干扰沉默结肠癌转移相关基因1（metastasis．associatedincoloncanceY1，MACCI），观察其对食管癌细胞株TE-1增殖、迁移及侵袭能力的影响。方法通过化学合成的特异性siRNA与阳离子脂质体Lipofectamine TM 2000形成复合体，转染食管癌细胞株TE-1，应用qRT-PCR、Westernblot检测转染后MACCl基因和蛋白表达水平；MTT法检测细胞生长增殖水平；划痕实验、Transwell实验检测细胞株干扰前后迁移侵袭能力的改变。结果siRNA．MACCl转染TE一1细胞后，与空白组比较，干扰组MACCl基因和蛋白的表达水平明显降低，分别降低71％和87％；MTT实验观察1—7d，干扰组较空白组、阴性对照组增殖速度明显降低（P〈0．05），第4天后效果更明显；划痕实验结果显示干扰组迁移划痕处的细胞（10．6±2．2）明显少于空白组（68．2±2．5），差异具有统计学意义（P〈0．05），各对照组间无统计学差异（P〉0．05）；Transwell实验结果显示干扰组穿过膜的TE-1细胞数目（4．2±1．9）较空白组（58．4±7．4）明显减少（P〈0．05），各对照组间无统计学差异（P〉0．05），表明干扰后TE-1细胞的迁移侵袭能力显著降低。结论siRNA．MACCl干扰导致TE-1细胞MACCl基因及蛋白表达水平明显下调；MACCl基因下调后，食管癌TE-1细胞的增殖、迁移、侵袭能力均明显降低，说明MACCl基因具有促进食管癌细胞增殖、迁移、侵袭的能力。

lncRNA01296在食管癌组织中的表达及其对食管癌TE-2细胞增殖和迁移的影响

目的:探究lncRNA01296在食管癌组织中的表达及其对食管癌TE-2细胞增殖和迁移的影响。方法:收集2017年1月至2018年9月承德医学院附属医院肿瘤科收治的36例食管癌组织及相应的癌旁组织,并培养人正常食管上皮细胞(HEEC)及人食管癌细胞系EC A109、TE-1及TE-2。用qPCR检测癌组织及EC A109、TE-1及TE-2细胞中lncRN A01296、小核核糖核蛋白A(SNRPA)及神经生长因子(NGF)mRNA的表达水平。重组慢病毒干扰载体转染食管癌细胞系及相应对照细胞系,分别分为干扰1组、干扰2组及对照组,WB实验检测转染后细胞SNRPA及NGF蛋白的表达水平,MTS实验检测转染后TE-2细胞的增殖能力,Transwell实验检测TE-2细胞侵袭和迁移能力。结果:lncRNA01296、SNRPA及NGF mRNA在食管癌组织及细胞系中呈高表达(均P<0.01),且lncRNA01296、SNRPA及NGF mRNA在低分化的TE-2细胞中表达高于其他癌细胞(均P<0.05)。干扰1组和干扰2组lncRNA01296、NGF mRNA表达水平明显低于对照组(均P<0.01),而SNRPA mRNA表达水平与对照组无明显差异(P>0.05);干扰1组和干扰2组SNRPA及NGF蛋白表达水平明显低于对照组(均P<0.01)。敲减48、72h后,干扰1组及干扰2组TE-2细胞相对增殖能力明显低于对照组(P<0.05或P<0.01);对照组、干扰1组及干扰2组侵袭细胞数分别为(72.0±6.3)、(36.6±4.3)及(33.9±3.7)个,迁移细胞数分别为(85.2±9.9)、(47.5±8.1)及(43.8±6.5)个,干扰1组及干扰2组侵袭及迁移细胞数显著低于对照组(均P<0.01);结论:lncRNA01296可通过上调SNRPA表达促进NGF介导的食管癌细胞的增殖和迁移,为临床食管癌诊断和治疗提供新的靶点。

沉默线粒体核糖体蛋白L35基因对人食管癌TE-1细胞生长的影响

目的:探讨慢病毒介导沉默线粒体核糖体蛋白L35 (MRPL35)基因对人食管癌TE-1细胞生长的影响,并阐明其机制。方法:选择3种人食管癌TE-1、ECA109和KYSE150细胞,采用实时定量PCR法检测3种细胞中MRPL35mRNA相对表达水平。食管癌TE-1细胞分为shMRPL35组和shCtrl组,分别加入沉默靶基因带有嘌呤霉素抗性的si-RNA慢病毒和带有嘌呤霉素抗性的阴性对照si-RNA慢病毒进行感染,建立稳定沉默MRPL35基因的食管癌细胞系,实时定量PCR及Western blotting法检测各组细胞中MRPL35基因沉默效率,采用CCK-8法检测各组细胞生长曲线,AnnexinⅤ-PE/7AAD双染色后流式细胞术检测细胞凋亡率。结果:3种食管癌细胞均表达MRPL35基因,3种细胞中MRPL35mRNA表达水平比较差异无统计学意义(P>0.05)。实时定量PCR法和Western blotting法检测,shMRPL35组TE-1细胞中MRPL35mRNA和蛋白表达水平明显低于shCtrl组(P<0.05)。与shCtrl组比较,shMRPL35组TE-1细胞生长速度明显降低(P<0.05),凋亡率明显升高(P<0.01)。结论:沉默MRPL35基因可抑制食管癌细胞TE-1增殖,并通过凋亡途径发挥作用。

紫草素对人食管癌TE-1细胞增殖、凋亡和细胞周期的影响及其可能的机制

目的:观察紫草素对人食管癌TE-1细胞增殖、凋亡和细胞周期的影响,并探究其作用机制。方法:采用不同浓度的紫草素(0、1、5、10µmol/L)处理TE-1细胞,MTT法检测24、48、72 h后各组细胞增殖水平;紫草素处理各组TE-1细胞48 h后,采用Hoechst 33258荧光染色观察细胞凋亡状况,流式细胞术检测细胞的凋亡水平及周期变化,Western blotting检测TRAP1/Akt/mTOR信号通路相关蛋白表达变化。结果:紫草素呈时间和浓度依赖性抑制TE-1细胞增殖(P<0.05或P<0.01);与对照组相比,紫草素能显著促进TE-1细胞凋亡(P<0.01),使TE-1细胞周期发生G0/G1期阻滞(P<0.05或P<0.01),同时降低TRAP1、p-Akt以及p-mTOR表达水平(P<0.05或P<0.01),以上作用具有剂量依赖性。结论:紫草素能显著抑制TE-1细胞的增殖,诱导细胞发生G0/G1期阻滞并促进其凋亡,这可能与其抑制TRAP1/Akt/mTOR信号通路有关。

没食子酸对人食管癌TE-1细胞的体外抑制作用及其机制

目的探究没食子酸(GA)对人食管癌TE-1细胞的体外抑制作用及潜在机制。方法MTT法检测GA作用24 h和48 h后对TE-1细胞增殖的影响,细胞荧光计数(CCK-F)法和倒置荧光显微镜观察GA作用后TE-1细胞的数量变化和形态变化,划痕实验检测细胞迁移能力的变化,平板集落形成实验检测GA对TE-1细胞集落形成能力的影响,流式细胞术检测细胞凋亡情况,荧光探针(DCFH-DA)法观察活性氧(ROS)产生情况;Western blot法检测胱天蛋白酶3(caspase-3)、caspase-9、B细胞淋巴瘤2(Bcl-2)、Bcl-2相关X蛋白(Bax)和细胞周期蛋白D1(cyclin D1)、cyclin D3的表达水平。结果GA能够明显降低TE-1细胞的增殖能力,且有时间和浓度依赖趋势,其对细胞的半数抑制浓度分别为(281.22±26.81)μmol/L(24 h)和(220.90±31.15)μmol/L(48 h)。与对照组比较,给药组细胞出现皱缩、排列稀疏、细胞核固缩等现象,且细胞数量明显减少。与对照组比较,给药组细胞的细胞迁移能力和集落形成能力均显著降低(P<0.01或P<0.05)。经100、300、500μmol/L的GA作用24 h后,细胞凋亡率分别为(6.21±0.32)%、(12.59±0.58)%和(15.41±0.41)%,均显著高于对照组的(5.29±0.28)%(P<0.01或P<0.05);除100μmol/L GA组外,其余给药组细胞ROS的产生水平均显著提高(P<0.01或P<0.05);与对照组比较,各给药组细胞中Bcl-2(仅GA 200μmol/L组)、Bax(GA 100μmol/L组除外)、caspase-3、caspase-9(GA 100μmol/L组除外)的表达水平均显著升高(P<0.01或P<0.05),Bcl-2(GA 100、200μmol/L组除外)、cyclin D1、cyclin D3蛋白的表达水平均显著降低(P<0.01或P<0.05)。结论GA能够抑制人食管癌TE-1细胞的增殖,限制其迁移能力及集落形成能力,促进其凋亡;上述作用可能与该成分可提高ROS水平并上调促凋亡蛋白caspase-3、caspase-9、Bax的表达,下调抗凋亡蛋白Bcl-2和细胞周期蛋白cyclin D1、cyclin D3的表达有关。

辐射抗性食管癌细胞亚系TE-1R的建立及其辐射抗拒机制的研究

目的建立辐射抗性食管癌细胞亚系TE-1R，并探讨其辐射诱导的凋亡性及辐射抗性机制。方法采用分次、间歇照射的方法（2Gy，5次）诱导人食管癌细胞系TE-1产生具有稳定辐射抗性的细胞亚系TE-1R，显微镜下观察细胞形态学差异。以TE-1和TE-1R细胞为实验对象，给予6MVX射线单次照射（2Gy），流式细胞仪分析细胞照射后的凋亡情况，RT—PCR法和Western Blot法分别检测食管癌TE-1、TE-1R细胞中复制蛋白AI（RPA1）mRNA和蛋白的表达情况。结果筛选出辐射抗性食管癌细胞亚系TE—1R。2Gy射线照射后12、24和48hTE-1R细胞的凋亡率低于TE—1细胞（P〈0．05）。RPA1 mRNA和蛋白在TE—1R细胞中的表达高于TE-1细胞（P〈0．05）。结论成功建立了辐射抗性的食管癌细胞亚系TE-1R，新的细胞亚系TE-1R比其亲本细胞系TE-1对射线更加抗拒，RPA1可能在食管癌细胞辐射抗性的修复中起着重要作用。

食管鳞癌组织中BARD1的表达及与淋巴结转移的关系

目的分析食管鳞癌(ESCC)中乳腺癌易感基因1相关环指结构域蛋白1(BARD1)的表达及与淋巴结转移的关系。方法纳入2018年1月至2021年12月本院收治且经组织病理学检查确诊的114例ESCC患者,免疫组化EnVision两步法检测癌组织与癌旁组织中BARD1的表达情况并比较BARD1阳性率,分析BARD1表达与ESCC临床病理特征的关系,建立Logistic回归模型分析BARD1表达对ESCC淋巴结转移的影响,绘制受试者工作特征(ROC)曲线分析BARD1表达对ES⁃CC淋巴结转移的预测价值。结果114例ESCC组织中BARD1阳性78例、阴性36例,对应癌旁组织中BARD1阳性23例、阴性91例,ESCC组织的BARD1阳性率为68.42%,高于癌旁组织的20.18%(χ^(2)=53.769,P<0.001)。BARD1表达与ESCC患者的T分期、分化程度和淋巴结转移有关(P<0.05),其中淋巴结转移组织的BARD1阳性率为80.36%(45/56),高于未转移组织的56.90%(33/58)。经Phi系数分析发现,BARD1表达与ESCC淋巴结转移呈正相关(r=0.276,P=0.003)。BARD1阳性是ESCC患者淋巴结转移的独立危险因素(OR=3.099,95%CI:1.339~7.175,P=0.008),且BARD1表达对ESCC患者淋巴结转移具有一定预测价值(AUC=0.636,P=0.020)。结论BARD1在ESCC中高表达,其与ESCC淋巴结转移密切相关,BARD1阳性会增加淋巴结转移风险,在评估ESCC淋巴结转移上有一定价值。

TW37对食管癌TE-1细胞迁移的影响

目的:观察TW37对食管癌TE-1细胞迁移的影响。方法:用0. 25、0. 50、1. 00、2. 00、4. 00、8. 00、16. 00、32. 00和64. 00μmol/L的TW37处理TE-1细胞24、48、72 h,采用MTT法检测细胞增殖。倒置显微镜下观察2、4μmol/L的TW37作用24 h对TE-1细胞形态的影响。划痕实验检测2、4μmol/L的TW37作用24、48 h对TE-1细胞迁移的影响。Western blot实验测定2、4μmol/L TW37作用24 h对TE-1细胞E-Cadherin、Vimentin以及N-Cadherin蛋白表达的影响。均设空白对照。结果:TW37抑制TE-1细胞增殖,呈时间和浓度依赖性。TW37作用后TE-1细胞由原来的梭形变成了卵圆形。TW37能够在较低浓度(2μmol/L)抑制TE-1细胞迁移,4μmol/L的TW37抑制迁移的作用更强(P <0. 05)。TW37能降低TE-1细胞中Vimentin、N-Cadherin的表达,上调E-Cadherin的表达(P <0. 05)。结论:TW37可能通过抑制EMT进程进而抑制TE-1细胞的迁移。

青藤碱通过MAPK/ERK/mTOR通路诱导自噬抑制人食管癌TE-1细胞增殖

目的:研究青藤碱对人食管癌TE-1细胞增殖、自噬的作用和机制。方法:将TE-1细胞分成对照组、青藤碱200 mg/L组、青藤碱400 mg/L组、青藤碱800 mg/L组。对照组不做处理,青藤碱200 mg/L组、青藤碱400 mg/L组、青藤碱800 mg/L组分别予以相应浓度的青藤碱干预。光学显微镜观察细胞形态改变,Hochest染色检测活细胞数,CCK8法检测细胞抑制率,流式细胞术检测细胞凋亡情况,透射电镜观察自噬小体情况,免疫荧光检测LC3表达情况,Western blotting检测LC3-Ⅰ、LC3-Ⅱ、Beclin-1、ERK1/2、p-ERK1/2、mTOR、p-mTOR蛋白相对表达量。结果:在200、400、800 mg/L青藤碱的作用下,TE-1细胞皱缩、变圆,漂浮在培养液中,活细胞数不断减少。青藤碱200 mg/L组、青藤碱400 mg/L组、青藤碱800 mg/L组活细胞数比例显著低于对照组(P<0.01),细胞抑制率、细胞凋亡率显著高于对照组(P<0.01);青藤碱200 mg/L组、青藤碱400 mg/L组、青藤碱800 mg/L组TE-1细胞内自噬小体多于对照组;青藤碱200 mg/L组、青藤碱400 mg/L组、青藤碱800 mg/L组TE-1细胞LC3表达、LC3-Ⅱ/LC3-Ⅰ比值、Beclin-1蛋白相对表达量均显著高于对照组(P<0.01),p-ERK1/2/ERK1/2及p-mTOR/mTOR比值均显著低于对照组(P<0.01)。结论:青藤碱能抑制人食管癌TE-1细胞增殖,其机制与抑制MAPK/ERK/mTOR通路和诱导自噬有关。